bluebird bio, Inc. (NASDAQ:BLUE) CEO Nick Leschly sold 3,350 shares of the firm’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $145.02, for a total value of $485,817.00. Following the completion of the transaction, the chief executive officer now owns 259,059 shares in the company, valued at approximately $37,568,736.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Nick Leschly also recently made the following trade(s):

  • On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The shares were sold at an average price of $145.14, for a total value of $1,023,237.00.
  • On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The shares were sold at an average price of $145.05, for a total value of $1,569,876.15.
  • On Friday, September 1st, Nick Leschly sold 46,833 shares of bluebird bio stock. The shares were sold at an average price of $122.27, for a total value of $5,726,270.91.
  • On Wednesday, August 30th, Nick Leschly sold 25,667 shares of bluebird bio stock. The shares were sold at an average price of $115.18, for a total value of $2,956,325.06.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 0.64% during trading on Tuesday, hitting $141.25. The stock had a trading volume of 671,819 shares. The stock has a 50 day moving average of $131.62 and a 200 day moving average of $105.10. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $145.70. The company’s market cap is $6.44 billion.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same period in the previous year, the firm earned ($1.59) earnings per share. The company’s revenue was up 977.4% compared to the same quarter last year. Equities analysts forecast that bluebird bio, Inc. will post ($6.80) EPS for the current fiscal year.

WARNING: “bluebird bio, Inc. (BLUE) CEO Nick Leschly Sells 3,350 Shares” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/24/bluebird-bio-inc-blue-ceo-nick-leschly-sells-3350-shares.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Hanseatic Management Services Inc. increased its stake in bluebird bio by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after acquiring an additional 27 shares during the last quarter. Teacher Retirement System of Texas increased its stake in bluebird bio by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 53 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in bluebird bio by 0.8% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after acquiring an additional 140 shares during the last quarter. Prudential Financial Inc. increased its stake in bluebird bio by 4.0% during the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after acquiring an additional 150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in bluebird bio by 0.5% during the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after acquiring an additional 151 shares during the last quarter.

A number of research firms have issued reports on BLUE. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a research report on Monday, October 16th. Jefferies Group LLC reiterated a “hold” rating and issued a $126.00 target price on shares of bluebird bio in a research report on Wednesday, October 11th. Maxim Group reiterated a “buy” rating and issued a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Leerink Swann reiterated an “outperform” rating and issued a $145.00 target price (up previously from $120.00) on shares of bluebird bio in a research report on Friday, October 6th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $118.81.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.